202 related articles for article (PubMed ID: 35621656)
21. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.
Hiraoka A; Kumada T; Kariyama K; Tada T; Tani J; Fukunishi S; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Kawata K; Yasuda S; Toyoda H; Ohama H; Nouso K; Tsutsui A; Nagano T; Itokawa N; Hayama K; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Michitaka K; Hiasa Y; Kudo M;
J Gastroenterol Hepatol; 2021 Jul; 36(7):1812-1819. PubMed ID: 33171524
[TBL] [Abstract][Full Text] [Related]
22. Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area.
Granata V; de Lutio di Castelguidone E; Fusco R; Catalano O; Piccirillo M; Palaia R; Izzo F; Gallipoli AD; Petrillo A
Radiol Med; 2016 Feb; 121(2):122-31. PubMed ID: 26345332
[TBL] [Abstract][Full Text] [Related]
23. Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma.
Kotani K; Enomoto M; Okada M; Yoshida K; Motoyama H; Fujii H; Hagihara A; Uchida-Kobayashi S; Morikawa H; Murakami Y; Tamori A; Kawada N
Clin J Gastroenterol; 2019 Aug; 12(4):355-360. PubMed ID: 31020569
[TBL] [Abstract][Full Text] [Related]
24. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk.
Kosaka Y; Kawaoka T; Aikata H; Suehiro Y; Yamaoka K; Ando Y; Namba M; Takeuchi Y; Fujii Y; Uchikawa S; Kodama K; Oya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Kimura T; Nagata Y; Chayama K
Clin J Gastroenterol; 2020 Oct; 13(5):839-843. PubMed ID: 31974811
[TBL] [Abstract][Full Text] [Related]
25. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.
Vogel A; Qin S; Kudo M; Su Y; Hudgens S; Yamashita T; Yoon JH; Fartoux L; Simon K; López C; Sung M; Mody K; Ohtsuka T; Tamai T; Bennett L; Meier G; Breder V
Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):649-658. PubMed ID: 34087115
[TBL] [Abstract][Full Text] [Related]
26. Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report.
Shimizu Y; Sunagozaka H; Yamagata K; Hirai H; Miura M; Yonemoto Y; Naito Y; Hasatani K; Yoshikawa J; Aoyagi H; Kaneko S
Clin J Gastroenterol; 2021 Apr; 14(2):645-649. PubMed ID: 33389590
[TBL] [Abstract][Full Text] [Related]
27. FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.
Nair A; Reece K; Donoghue MB; Yuan WV; Rodriguez L; Keegan P; Pazdur R
Oncologist; 2021 Mar; 26(3):e484-e491. PubMed ID: 33044793
[TBL] [Abstract][Full Text] [Related]
28. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
[TBL] [Abstract][Full Text] [Related]
29. Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma.
Kim S; Kim KH; Kim BK; Park JY; Ahn SH; Kim DY; Kim SU
J Gastroenterol Hepatol; 2021 May; 36(5):1317-1325. PubMed ID: 33217054
[TBL] [Abstract][Full Text] [Related]
30. Minimal impact of lenvatinib (Lenvima®) on muscle mass in advanced hepatocellular carcinoma and implications for treatment duration. Two cases from the REFLECT study.
Rinninella E; Cintoni M; Raoul P; Mele MC; De Gaetano AM; Marini MG; Mora V; Gasbarrini A
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):10132-10138. PubMed ID: 31799685
[TBL] [Abstract][Full Text] [Related]
31. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Value of Quantitative Perfusion Computed Tomography Technique in the Assessment of Tumor Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Ippolito D; Querques G; Pecorelli A; Talei Franzesi C; Okolicsanyi S; Strazzabosco M; Sironi S
J Comput Assist Tomogr; 2019; 43(2):206-213. PubMed ID: 30407241
[TBL] [Abstract][Full Text] [Related]
34. Lenvatinib Rechallenge After Ramucirumab Treatment Failure for Hepatocellular Carcinoma.
Komatsu S; Yano Y; Kido M; Kuramitsu K; Gon H; Fukushima K; Urade T; So S; Yanagimoto H; Toyama H; Kodama Y; Fukumoto T
Anticancer Res; 2021 Sep; 41(9):4555-4562. PubMed ID: 34475083
[TBL] [Abstract][Full Text] [Related]
35. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
36.
Dong W; Zou M; Sheng J; Zhou W; Wang Y; Zhang Y; Li J; Qian Y; Yu H; Lu T; Pan J; Zhu Y; Qu S; Yang Z; Lin Q; Zhao L; Cong W; Xu B; Zhang C; Liu H; Dong H
J Gastrointest Oncol; 2023 Dec; 14(6):2479-2499. PubMed ID: 38196518
[TBL] [Abstract][Full Text] [Related]
37. Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound.
Kamachi N; Nakano M; Okamura S; Niizeki T; Iwamoto H; Shimose S; Shirono T; Noda Y; Kuromatsu R; Koga H; Torimura T
Cancer Rep (Hoboken); 2022 Feb; 5(2):e1471. PubMed ID: 34105904
[TBL] [Abstract][Full Text] [Related]
38. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
Kaufmann S; Thaiss WM; Schulze M; Bitzer M; Lauer U; Nikolaou K; Horger M
Acta Radiol; 2018 Jul; 59(7):765-772. PubMed ID: 28927298
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of efficacy of transcatheter arterial chemoembolization combined with computed tomography-guided radiofrequency ablation for hepatocellular carcinoma using magnetic resonance diffusion weighted imaging and computed tomography perfusion imaging: A prospective study.
Shao GL; Zheng JP; Guo LW; Chen YT; Zeng H; Yao Z
Medicine (Baltimore); 2017 Jan; 96(3):e5518. PubMed ID: 28099329
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]